I-Mab (NASDAQ:IMAB) has received an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.

Brokerages have set a 12 month consensus price objective of $33.00 for the company and are anticipating that the company will post ($0.51) EPS for the current quarter, according to Zacks. Zacks has also given I-Mab an industry rank of 51 out of 254 based on the ratings given to related companies.

Several research firms have weighed in on IMAB. Zacks Investment Research upgraded shares of I-Mab from a “hold” rating to a “buy” rating and set a $35.00 price target on the stock in a research report on Saturday, June 20th. ValuEngine upgraded shares of I-Mab from a “hold” rating to a “buy” rating in a research report on Thursday, April 2nd.

IMAB stock traded down $1.04 on Tuesday, hitting $29.91. The company had a trading volume of 11,763 shares, compared to its average volume of 53,683. I-Mab has a 12-month low of $9.30 and a 12-month high of $32.89. The company has a 50-day moving average of $23.67. The company has a market capitalization of $1.71 billion and a PE ratio of -1.03.

I-Mab (NASDAQ:IMAB) last issued its earnings results on Tuesday, March 31st. The company reported ($17.05) earnings per share (EPS) for the quarter. The company had revenue of $0.11 million for the quarter. Sell-side analysts forecast that I-Mab will post -2.25 EPS for the current year.

About I-Mab

I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders worldwide. It is developing TJ202, a CD38 antibody in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; TJ101, a long-acting human growth hormone that is in Phase II clinical trials to treat pediatric growth hormone deficiency; and TJ301, a IL-6 blocker in Phase II clinical trials for the treatment of ulcerative colitis and other autoimmune diseases.

Recommended Story: Net Margin – Understanding the Different Kinds of Profit

Get a free copy of the Zacks research report on I-Mab (IMAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for I-Mab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for I-Mab and related companies with MarketBeat.com's FREE daily email newsletter.